{"id":"https://openalex.org/W2564097003","doi":"https://doi.org/10.1158/1538-7445.am2015-1619","title":"Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma","display_name":"Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma","publication_year":2015,"publication_date":"2015-08-01","ids":{"openalex":"https://openalex.org/W2564097003","doi":"https://doi.org/10.1158/1538-7445.am2015-1619","mag":"2564097003"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2015-1619","doi":"https://doi.org/10.1158/1538-7445.am2015-1619","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-1619","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040149772","display_name":"Nicole R. Infarinato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Infarinato","raw_affiliation_strings":["1Children's Hospital of Philadelphia, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Hospital of Philadelphia, Philadelphia, PA;","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100784577","display_name":"Jin Kee Park","orcid":"https://orcid.org/0000-0002-4597-6344","observed_orcids":["https://orcid.org/0000-0002-4597-6344"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jin Park","raw_affiliation_strings":["2University of Pennsylvania School of Medicine, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pennsylvania School of Medicine, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102864493","display_name":"Renata Sano","orcid":"https://orcid.org/0000-0001-9630-3388","observed_orcids":["https://orcid.org/0000-0001-9630-3388"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renata Sano","raw_affiliation_strings":["1Children's Hospital of Philadelphia, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Hospital of Philadelphia, Philadelphia, PA;","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053226567","display_name":"Kateryna Krytska","orcid":"https://orcid.org/0009-0009-8402-8687","observed_orcids":["https://orcid.org/0009-0009-8402-8687"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kateryna Krytska","raw_affiliation_strings":["1Children's Hospital of Philadelphia, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Hospital of Philadelphia, Philadelphia, PA;","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019240347","display_name":"Hannah T. Ryles","orcid":"https://orcid.org/0000-0001-5126-9075","observed_orcids":["https://orcid.org/0000-0001-5126-9075"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah Ryles","raw_affiliation_strings":["1Children's Hospital of Philadelphia, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Hospital of Philadelphia, Philadelphia, PA;","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023840148","display_name":"Helen Y. Zou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen Zou","raw_affiliation_strings":["3Pfizer Inc, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer Inc, La Jolla, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043961547","display_name":"Nathan Lee","orcid":"https://orcid.org/0000-0003-2628-6599","observed_orcids":["https://orcid.org/0000-0003-2628-6599"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan Lee","raw_affiliation_strings":["3Pfizer Inc, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer Inc, La Jolla, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004738391","display_name":"Tod Smeal","orcid":"https://orcid.org/0009-0000-0320-7451","observed_orcids":["https://orcid.org/0009-0000-0320-7451"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tod Smeal","raw_affiliation_strings":["3Pfizer Inc, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Pfizer Inc, La Jolla, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073959537","display_name":"Mark A. Lemmon","orcid":"https://orcid.org/0000-0002-3379-5319","observed_orcids":["https://orcid.org/0000-0002-3379-5319"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Lemmon","raw_affiliation_strings":["2University of Pennsylvania School of Medicine, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pennsylvania School of Medicine, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030496565","display_name":"Ya\u00ebl P. Moss\u00e9","orcid":"https://orcid.org/0000-0002-3463-0399","observed_orcids":["https://orcid.org/0000-0002-3463-0399"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yael P. Mosse","raw_affiliation_strings":["1Children's Hospital of Philadelphia, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Children's Hospital of Philadelphia, Philadelphia, PA;","institution_ids":["https://openalex.org/I1335321130"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"15_Supplement","first_page":"1619","last_page":"1619"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9375,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.05510000139474869,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuroblastoma","display_name":"neuroblastoma","score":0.9670000076293945},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.9039999842643738},{"id":"https://openalex.org/keywords/alk-mutations","display_name":"ALK mutations","score":0.8510000109672546},{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.9610000252723694},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.6919999718666077},{"id":"https://openalex.org/keywords/atp-competitive-kinase-inhibitors","display_name":"ATP-competitive kinase inhibitors","score":0.7070000171661377},{"id":"https://openalex.org/keywords/ros1","display_name":"ROS1","score":0.5789999961853027},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7120000123977661},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6790000200271606},{"id":"https://openalex.org/keywords/kinase-inhibitor-selectivity","display_name":"kinase selectivity","score":0.5090000033378601}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9957314729690552},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.8003631830215454},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.7774998545646667},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5962889790534973},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.4803277552127838},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.4520835280418396},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.4411763846874237},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.4288186728954315},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.41115105152130127},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4095459282398224},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.36075159907341003},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3370690941810608},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.332447350025177},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.19552654027938843},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18717840313911438},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.12756291031837463},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.11557969450950623},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2015-1619","doi":"https://doi.org/10.1158/1538-7445.am2015-1619","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-1619","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2103600998","https://openalex.org/W2462717932","https://openalex.org/W2337713490","https://openalex.org/W2146396128","https://openalex.org/W171311624","https://openalex.org/W2126298634","https://openalex.org/W2404235140","https://openalex.org/W2566076571","https://openalex.org/W1998616043","https://openalex.org/W2056503379"],"abstract_inverted_index":{"Abstract":[0],"Neuroblastomas":[1],"(NBs)":[2],"harboring":[3],"activating":[4],"point":[5],"mutations":[6],"in":[7,42,55,98,134,151,204,229,237,240,292,303,406],"the":[8,56,109,180,335,354,367,412,417],"kinase":[9,14,251],"domain":[10],"of":[11,39,94,183,188,196,254,272,306,317,369,411,416],"anaplastic":[12],"lymphoma":[13],"(ALK)":[15],"are":[16,243],"differentially":[17],"sensitive":[18],"to":[19,48,63,74,313,350,359,404],"ALK":[20,40,67,96,257,266,340,398],"inhibition":[21,228,252,299],"by":[22,245],"crizotinib":[23,49,92,126,291,351,405],"(Bresler":[24],"et":[25],"al.":[26],"2011).":[27],"The":[28,396],"F1174L":[29,110,143,278],"and":[30,50,72,100,111,139,175,192,213,239,296,319,352],"F1245C":[31,112,137],"amino":[32],"acid":[33],"substitutions,":[34],"which":[35,358],"comprise":[36],"38.5%":[37],"(mycancergenome.org)":[38],"aberrations":[41],"NB,":[43,99],"also":[44],"confer":[45],"intrinsic":[46],"resistance":[47,93,233,349,403],"present":[51],"a":[52,65,105,116,186,193,338,361],"significant":[53],"obstacle":[54],"clinic.":[57],"Therefore,":[58],"our":[59,246],"goal":[60],"has":[61],"been":[62],"identify":[64],"next-generation":[66,256,397],"inhibitor":[68,341,399],"with":[69,211,231,277,347],"improved":[70],"selectivity":[71],"potency":[73,191,289],"target":[75],"these":[76,95,332],"resistant":[77],"mutants":[78],"effectively.":[79],"We":[80],"demonstrate":[81],"here":[82],"that":[83,179,337],"PF-06463922":[84,129,184,212,219,259,282,365,400],"(Pfizer),":[85],"an":[86],"ATP-competitive,":[87],"macrocyclic":[88],"ALK/ROS1":[89],"inhibitor,":[90],"overcomes":[91,401],"variants":[97,267],"exerts":[101],"unprecedented":[102],"activity":[103,182],"as":[104],"single":[106],"agent":[107],"against":[108,263],"ALK-mutated":[113,370],"tumors.":[114],"At":[115],"tenfold":[117],"lower":[118],"dose":[119],"(10":[120],"mg/kg)":[121],"than":[122,234,290],"typically":[123],"used":[124],"for":[125,166,269,345,364,366,420],"(100":[127],"mg/kg),":[128],"induces":[130,323],"complete":[131,164],"tumor":[132,156],"regression":[133],"patient-derived":[135],"(COG-N-426x,":[136],"ALK-mutated)":[138,144],"cell":[140,207],"line-derived":[141],"(SY5Y,":[142],"xenograft":[145],"mouse":[146],"models.":[147],"Whereas":[148],"crizotinib-treated":[149],"mice":[150,161],"both":[152,189],"models":[153],"experience":[154],"rapid":[155],"growth":[157,227],"on":[158],"therapy,":[159],"PF-06463922-treated":[160],"showed":[162,283],"sustained":[163],"responses":[165],"several":[167,255],"weeks":[168],"even":[169],"after":[170],"treatment":[171,210,368],"was":[172,260,300],"discontinued.":[173],"Cell-based":[174],"biochemical":[176,247],"analyses":[177],"indicate":[178],"superior":[181,298],"is":[185,220,311],"function":[187],"higher":[190,288],"broader":[194],"spectrum":[195],"effectiveness":[197],"across":[198],"mutants.":[199],"ATP":[200],"levels":[201],"were":[202],"measured":[203],"ten":[205],"NB":[206],"lines":[208],"upon":[209],"crizotinib;":[214],"at":[215,225,284],"120":[216],"hours":[217],"post-treatment,":[218],"26-38":[221],"times":[222],"more":[223],"effective":[224,262],"inducing":[226],"cells":[230],"primary":[232,348,402],"crizotinib.":[235],"These":[236],"vitro":[238],"vivo":[241],"results":[242,333],"corroborated":[244],"experiments.":[248],"In":[249,280],"comparative":[250],"studies":[253],"inhibitors,":[258],"most":[261],"frequently":[264],"observed":[265,302],"accounting":[268],"approximately":[270],"75%":[271],"neuroblastoma":[273],"samples,":[274],"including":[275],"those":[276],"mutations.":[279],"vitro,":[281],"least":[285],"3-4":[286],"fold":[287],"peptide":[293],"phosphorylation":[294],"assays,":[295],"its":[297],"consistently":[301],"cellular":[304],"analysis":[305],"transforming":[307],"ability.":[308],"Further":[309],"investigation":[310],"necessary":[312],"elucidate":[314],"PF-06463922's":[315],"mechanism":[316],"action":[318],"reveal":[320],"how":[321],"it":[322],"apoptotic":[324],"signaling":[325],"networks":[326],"without":[327],"abrogating":[328],"phospho-ALK.":[329],"Taken":[330],"together,":[331],"support":[334],"argument":[336],"modified":[339],"may":[342],"improve":[343],"outcomes":[344],"patients":[346],"provide":[353],"preclinical":[355],"basis":[356],"from":[357],"design":[360],"clinical":[362],"trial":[363],"NBs.":[371],"Citation":[372],"Format:":[373],"Nicole":[374],"Infarinato,":[375],"Jin":[376],"Park,":[377],"Renata":[378],"Sano,":[379],"Kateryna":[380],"Krytska,":[381],"Hannah":[382],"Ryles,":[383],"Helen":[384],"Zou,":[385],"Nathan":[386],"Lee,":[387],"Tod":[388],"Smeal,":[389],"Mark":[390],"A.":[391],"Lemmon,":[392],"Yael":[393],"P.":[394],"Mosse.":[395],"neuroblastoma.":[407],"[abstract].":[408],"In:":[409],"Proceedings":[410],"106th":[413],"Annual":[414],"Meeting":[415],"American":[418],"Association":[419],"Cancer":[421,431],"Research;":[422],"2015":[423],"Apr":[424],"18-22;":[425],"Philadelphia,":[426],"PA.":[427],"Philadelphia":[428],"(PA):":[429],"AACR;":[430],"Res":[432],"2015;75(15":[433],"Suppl):Abstract":[434],"nr":[435],"1619.":[436],"doi:10.1158/1538-7445.AM2015-1619":[437]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2017-01-06T00:00:00"}